Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 7:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Scopolamine Clear all
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray

NCT02155309
View directory record Official record
Conditions
Motion Sickness
Interventions
Scopolamine, Placebo
Drug
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 30, 2026, 7:47 PM EDT
Terminated Phase 2 Interventional Results available

The Antidepressant Efficacy of the Anticholinergic Scopolamine

NCT00369915
View directory record Official record
Conditions
Unipolar Depression, Bipolar Depression
Interventions
Scopolamine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 10, 2016 · Synced Oct 30, 2026, 7:47 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance

NCT05886660
View directory record Official record
Conditions
Motion Sickness, Space, Motion Sickness, Sea Sickness
Interventions
DPI-386 Nasal Gel, Placebo Nasal Gel
Drug
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2024 · Synced Oct 30, 2026, 7:47 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Cholinergic Modulation of Condition and Emotion in Mood Disorders: Functional Neuroimaging Studies

NCT00055575
View directory record Official record
Conditions
Mood Disorders, Healthy, Unipolar Depression, Bipolar Depression
Interventions
Scopolamine Nasal Spray
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 55 Years
Enrollment
197 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Oct 30, 2026, 7:47 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Scopolamine Patch Pharmacokinetics in Healthy Adults

NCT03029650
View directory record Official record
Conditions
Healthy
Interventions
Transderm Scop®, Intravenous scopolamine hydrobromide
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 21, 2018 · Synced Oct 30, 2026, 7:47 PM EDT
Enrolling by invitation Early Phase 1 Interventional Accepts healthy volunteers

Representation of Spatiotemporal Information in Human Episodic Memory and Navigation

NCT07423923
View directory record Official record
Conditions
Scopolamine or Placebo, Schema to Organize Memory or no Schema
Interventions
Scopolamine
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
2
States / cities
Tucson, Arizona • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 30, 2026, 7:47 PM EDT
Terminated Phase 2 Interventional Results available

A Study of the Use of IV Scopolamine to Augment the Efficacy of Electroconvulsive Therapy (ECT)

NCT01312844
View directory record Official record
Conditions
Depression
Interventions
Scopolamine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 30, 2026, 7:47 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Safety and Efficacy of Naltrexone and Scopolamine Utilized in the Treatment of Major Depression

NCT03386448
View directory record Official record
Conditions
Depression
Interventions
Scopolamine and naltrexone, placebo arm
Drug
Lead sponsor
The Taub Group
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Oct 30, 2026, 7:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparison of Aprepitant Versus Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting

NCT00717054
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Aprepitant, Scopolamine
Drug
Lead sponsor
Drexel University
Other
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 30, 2026, 7:47 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Study of the Safety and Efficacy of DPI-386 Nasal Gel on Ocean-Going Vessels

NCT03920644
View directory record Official record
Conditions
Prevention of Nausea Associated With Motion Sickness, Treatment of Nausea Associated With Motion Sickness
Interventions
Scopolamine Transdermal Patch [Transderm Scop], Scopolamine, Placebo Patch, Placebo Gel
Drug
Lead sponsor
Naval Aeromedical Research Unit, Dayton
Federal
Eligibility
18 Years to 59 Years
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 19, 2019 · Synced Oct 30, 2026, 7:47 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Scopolamine Patch and Acupressure Point P6 Stimulation for Reduction of Nausea and Vomiting During Cesarean Section

NCT02960113
View directory record Official record
Conditions
Nausea, Vomiting, Satisfaction
Interventions
scopolamine patch, acupressure point P6
Drug · Device
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Oct 30, 2026, 7:47 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Assessment Of The Effects Of Single Doses Of An Investigational Drug, Given Alone Or With Donepezil, On Scopolamine-Induced Changes In Memory And Learning In Healthy Adults

NCT01345864
View directory record Official record
Conditions
Healthy
Interventions
Scopolamine + Donepezil Placebo + PF-04995274 Placebo, Scopolamine + Donepezil 5 mg + PF-04995274 Placebo, Scopolamine + Donepezil 10mg + PF-04995274 Placebo, Scopolamine + Donepezil Placebo + PF-04995274 0.25 mg, Scopolamine + Donepezil Placebo + PF-04995274 15 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Oct 30, 2026, 7:47 PM EDT
Completed No phase listed Observational

A Novel Usage of Transdermal Scopolamine in Reducing Narcotic Usage in Outpatient Hand Surgery

NCT04008264
View directory record Official record
Conditions
Post Operative Pain Management
Interventions
Scopolamine Patch (Transderm V)
Drug
Lead sponsor
Alexander M Spiess, MD
Other
Eligibility
18 Years to 55 Years
Enrollment
74 participants
Timeline
2019 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 8, 2022 · Synced Oct 30, 2026, 7:47 PM EDT
Completed Not applicable Interventional Results available

Comparison of Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting

NCT00659737
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Aprepitant, Scopolamine
Drug
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Oct 30, 2026, 7:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Nebulizer Delivery of Intranasal Scopolamine

NCT04999449
View directory record Official record
Conditions
Scopolamine, Motion Sickness
Interventions
Scopolamine, Placebo
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
21 Years to 49 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 30, 2026, 7:47 PM EDT
Completed Phase 1 Interventional

Generalization of Extinction Learning

NCT01900301
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Scopolamine, intranasal placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Oct 30, 2026, 7:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers

NCT03030105
View directory record Official record
Conditions
Alzheimer Disease
Interventions
BPN14770, BPN14770 placebo, Donepezil, Donepezil placebo, Scopolamine 0.6 MG/ML, Scopolamine placebo
Drug
Lead sponsor
Tetra Discovery Partners
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 30, 2026, 7:47 PM EDT
Completed Phase 2 Interventional Results available

(Hyoscine Butylbromide) for Abdominal Pain Associated With Cramping on Demand Basis

NCT00932737
View directory record Official record
Conditions
Abdominal Pain
Interventions
Placebo, HBB 20 mg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
19
States / cities
Westlake Village, California • Hollywood, Florida • Jupiter, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Oct 30, 2026, 7:47 PM EDT
Withdrawn Not applicable Interventional

Ketamine and Scopolamine Infusions for Treatment-resistant Major Depressive Disorder

NCT01613820
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine, Scopolamine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Oct 30, 2026, 7:47 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Intramuscular Administration of Scopolamine

NCT04314713
View directory record Official record
Conditions
Medical Countermeasures, Organophosphate Poisoning
Interventions
Scopolamine Hydrobromide Trihydrate
Drug
Lead sponsor
Battelle Memorial Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 30, 2026, 7:47 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

TAK-071 Scopolamine-Induced Cognitive Impairment Study

NCT02918266
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Scopolamine, TAK-071, Donepezil, Scopolamine Placebo, TAK-071 Placebo, Donepezil Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 30, 2026, 7:47 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance

NCT05852730
View directory record Official record
Conditions
Motion Sickness, Space, Motion Simulation, Parabolic Flight
Interventions
DPI-386 Nasal Gel, Other (e.g., promethazine, meclizine)
Drug
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 30, 2026, 7:47 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects

NCT03988530
View directory record Official record
Conditions
Motion Sickness
Interventions
Scopolamine, Placebo Nasal Gel
Drug · Other
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
55 Years and older
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 30, 2026, 7:47 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

PET and MRI Imaging With Scopolamine at the Muscarinic M1 Receptor

NCT06014385
View directory record Official record
Conditions
Muscarinic Receptor Occupancy
Interventions
Scopolamine, [11C]EMO ([11C]LSN3172176)
Drug · Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Oct 30, 2026, 7:47 PM EDT